Dr Lewis Quayle PhD, MRes, BSc (Hons), FHEA

Senior Lecturer in Data Science and Analytics

Summary

Lewis is a data scientist and bioinformatician who transitioned into computational biology and healthcare data analytics from laboratory-based research in the field of cancer cell biology during his post-doctoral work. Given his interdisciplinary background, Lewis has experience with a broad variety of data science and bioinformatic analytical workflows, including high-performance computing-based pipeline development, microarray and next-generation sequencing data processing, large-scale clinical data analysis, unsupervised and supervised machine learning, text mining for topic modelling and sentiment analysis, interaction network construction and interrogation, and geospatial data analysis, amongst others.

While committed to teaching analytical skills to the next generation of data scientist, Lewis remains fully-research active. He is currently a member of two Genomics England 100,000 Genomes Project working groups and a collaborator on several clinical research, pure research, and digital healthcare analytics projects involving large-scale genomic and clinical data analysis and predictive modelling in the fields of bladder cancer, ovarian cancer, breast cancer, and gestational trophoblastic disease.

E-mail

About

Lewis obtained his PhD in the Department of Oncology & Metabolism at The University of Sheffield Medical School in October 2017. His PhD project focussed on developing novel models of mitotic quiescence in human breast cancer and his early postdoctoral work focussed on characterising the cancer cell populations isolated from these models using various approaches, including next-generation sequencing and bioinformatic analytics. In 2019, he undertook a three-month training placement in high-performance computing (HPC) at the Kinghorn Centre for Clinical Genomics in Sydney, Australia, and later that year he moved to a two-year post as a postdoctoral cancer bioinformatician. In June 2022, he moved to a full-time role as cancer bioinformatician embedded within the Sheffield Bioinformatics Core Facility working various clinical projects involving large-scale next-generation sequencing and clinical data analysis and was appointed as a Senior Lecturer in Data Science and Analytics in the Department of Computing in May 2023.

Lewis began teaching during his MRes and continued to supervise undergraduate, MSc and PhD research project throughout his own PhD and post-doctoral career. He has previously lectured on the topics of next generation sequencing, bioinformatic analytics, and best practices in computational research as part of MSc Translational Oncology and MSc Molecular Medicine at the University of Sheffield, and currently holds a three-year honorary post as Senior Lecturer in Bioinformatics in the Department of Oncology and Metabolism at the University of Sheffield. In recognition of his commitment to professionalism in learning and teaching in higher education and meeting all points of the Professional Standards Framework (2023), he has been awarded Fellowship of Advance HE (FHEA) and is also certified by The Carpentries to teach foundational coding and data science skills to researchers under the core curriculum of Data Carpentry, Library Carpentry, and Software Carpentry.

Teaching

Subject area
Digital Analytics and Technologies

Courses
MSc Big Data Analytics
MSc Healthcare Analytics and Artificial Intelligence

Modules
Learning Systems and Data Analysis for Healthcare
Ethics of Healthcare Information
Advanced Data Management Project

Research

Lewis remains fully-research active in his areas of domain expertise and his current research projects span multiple human cancers. He is currently a member of two Genomics England 100,000 Genomes Project working groups aiming to create a mutational map in bladder and ovarian cancer cohorts, bioinformatician on the GUSTO phase II clinical trial, co-investigator on a project aiming to develop a test for prediction of response to chemotherapy in gestational trophoblastic disease, and co-investigator on project continuing his early post-doctoral work which aim to identify molecular drivers and biomarkers of metastatic dormancy in breast cancer. He is also involved in several smaller clinical and pure research projects in a range of areas including high-throughput screening, public healthcare data analytics, and predictive modelling of prognostic risk factors in a range of settings.

Publications

Journal articles

Morita, M., Arshad, F., Quayle, L., George, C.N., Lefley, D.V., Kalajzic, I., ... Ottewell, P.D. (2024). Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model. Bone Reports. http://doi.org/10.1016/j.bonr.2024.101795

Griffin, J., Down, J., Quayle, L., Heath, P.R., Gibb, E.A., Davicioni, E., ... Catto, J.W.F. (2024). Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology: Clinical Research, 10 (2). http://doi.org/10.1002/2056-4538.12363

Catto, J.W.F., Mandrik, O., Quayle, L.A., Hussain, S.A., McGrath, J., Cresswell, J., ... Cumberbatch, M. (2023). Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU international, 131 (6), 734-744. http://doi.org/10.1111/bju.15970

Quayle, L.A., Spicer, A., Ottewell, P.D., & Holen, I. (2021). Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy. Cancers, 13 (16). http://doi.org/10.3390/cancers13163922

Tulotta, C., Lefley, D.V., Moore, C.K., Amariutei, A.E., Spicer-Hadlington, A.R., Quayle, L.A., ... Ottewell, P.D. (2021). IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj breast cancer, 7 (1). http://doi.org/10.1038/s41523-021-00305-w

Quayle, L.A., Ottewell, P.D., & Holen, I. (2018). Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical & experimental metastasis, 35 (8), 831-846. http://doi.org/10.1007/s10585-018-9946-2

Quayle, L., Ottewell, P., & Holen, I. (2018). Therapeutic resistance and stemness in mitoticallyquiescent human breast cancer cells [abstract only]. Breast Cancer Research and Treatment, 167 (1), 393-394. http://doi.org/10.1007/s10549-017-4585-x

Quayle, L.A., Pereira, M.G., Scheper, G., Wiltshire, T., Peake, R.E., Hussain, I., ... Bates, T.E. (2017). Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action. Oncotarget, 8 (51), 88670-88688. http://doi.org/10.18632/oncotarget.20858

Quayle, L., Park, S., McDonnell, D.P., Ottewell, P.D., & Holen, I. (2017). Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells. Cancer Research, 77 (4_Supp). http://doi.org/10.1158/1538-7445.sabcs16-p3-07-14

Quayle, L., Ottewell, P.D., & Holen, I. (2015). Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current cancer drug targets, 15 (6), 469-480. http://doi.org/10.2174/1568009615666150506092443

Conference papers

Crabb, S., Hussain, S., Oughton, J., Swain, J., Cairns, D., Collinson, M., ... Catto, J. (2024). Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO [abstract only]. Journal of Clinical Oncology, 42 (16 sup). http://doi.org/10.1200/JCO.2024.42.16_suppl.TPS4621

Griffin, J., Down, J., Quayle, L., Heath, P., & Catto, J. (2023). Pathology against the clock: Verification of gene expression subtyping for the GUSTO clinical trial [abstract only]. The Journal of Pathology, 261 (S1). http://doi.org/10.1002/path.6226

Quayle, L., Ottewell, P., & Holen, I. (2018). Therapeutic Resistance and Stemness in Mitotically Quiescent Human Breast Cancer Cells [Abstract only]. Breast Cancer Research and Treatment, 167, 309-405. http://doi.org/10.1007/s10549-017-4585-x

Quayle, L., Park, S.H., McDonnell, D., Ottewell, P., & Holen, I. (2017). Targeting ERR-α Regulated Lactate Metabolism Eliminates Drug-Resistant Breast Cancer Cells. In 2016 San Antonio Breast Cancer Symposium, 2016 - 2016.

Book chapters

Holen, I., & Quayle, L. (2021). Stem cell niches in bone and their roles in cancer metastasis. In Advances in Stem Cells and their Niches. (pp. 35-62). Elsevier: http://doi.org/10.1016/bs.asn.2020.09.002

Ottewell, P.D., & Quayle, L.A. (2020). Tumor Dormancy in The Bone. In Encyclopedia of Bone Biology. (pp. 166-179). Elsevier: http://doi.org/10.1016/b978-0-12-801238-3.11239-5

Theses / Dissertations

Quayle, L. (2018). Identification and Characterisation of Mitotically Quiescent Sub-Clones in Breast Cancer. (Doctoral thesis). Supervised by Ottewell, P., & Holen, I.